A century of research on neuromodulation interventions: A scientometric analysis of trends and knowledge maps

Michel Sabe a,*, Adi Sulstarova a, Chaomei Chen b, Joshua Hyde c, Emmanuel Poulet d,e,f,g,h,i, André Aleman j, Jonathan Downar k,l,m,n,o, Valerie Brandt p,q, Luc Mallet r,s,t, Othman Sentissi a, Michael A. Nitsche u,v, Marom Bikson w, André Russowsky Brunoni x,y, Samuele Cortese z,aa,ab,ac,ad, Marco Solmi ae,af,ag,ah,ai

a Division of Adult Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 2, Chemin du Petit-Bel-Air, CH-1226 Thonex, Switzerland
b College of Computing & Informatics, Drexel University, Philadelphia, PA, USA
c Centre for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK
d Centre Hospitalier Le Vinatier, Bron, France
e INSERM, U1028, CNRS, UMR5292, France
f University Lyon 1, F-69000 Villeurbanne, France
g Lyon Neuroscience Research Center, PSYR2 Team, F-69000 Lyon, France
h Université Jean Monnet Saint Etienne, F-42000, France
i Psychiatric Emergency Service, Hopices Civils de Lyon, F-69005 Lyon, France
j University of Groningen, Department of Biomedical Sciences of Cells & Systems, Cognitive Neuroscience Center, University Medical Center Groningen, Groningen, the Netherlands
k Krembil Research Institute, University Health Network, Toronto, ON, Canada
l MRI-Guided TMS Clinic, University Health Network, Toronto, ON, Canada
m Centre for Mental Health, University Health Network, Toronto, ON, Canada
n Institute of Medical Science, University of Toronto, Toronto, ON, Canada
o Department of Psychiatry, University of Toronto, Toronto, ON, Canada
p Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK
q Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
r Université Paris Est Créteil, DMU IMPACT, Département Médical Universitaire de Psychiatrie et d’Addictologie, Hopitaux Universitaires Henri Mondor, Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France
s Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, INSERM, CNRS, Paris, France
t Department of Mental Health and Psychiatry, Global Health Institute, University of Geneva, Geneva, Switzerland
u Dept. Psychology and Neurosciences, Leibniz Research Centre for Work Environment and Human Factors at TU Dortmund, Germany
v Bielefeld University, University Hospital OWL, Protestant Hospital of Bethel Foundation, University Clinic of Psychiatry and Psychotherapy and University Clinic of Child and Adolescent Psychiatry and Psychotherapy, Germany
w Department of Biomedical Engineering, City College of New York, New York, NY, USA
x Departamento de Clínica Médica da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, São Paulo, Brazil
y Instituto de Psiquiatria da Faculdade de Medicina da USP, São Paulo, Brazil
z Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK
aa Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK
ab Solent NHS Trust, Southampton, UK
ac Hazenfeld Children’s Hospital at NYU Langone, New York University Child Study Center, New York, NY, USA
ad Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK
ae Department of Psychiatry, University of Ottawa, Ontario, Canada
af Department of Mental Health, The Ottawa Hospital, Ontario, Canada
ag Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa, Ottawa, Ontario, Canada
ah School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
ai Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

* Corresponding author.
E-mail address: michel.sabe@hcuge.ch (M. Sabe).

https://doi.org/10.1016/j.neubiorev.2023.105300
Received 21 February 2023; Received in revised form 24 May 2023; Accepted 27 June 2023
Available online 30 June 2023
0149-7634/© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Interest in neurostimulation interventions has significantly grown in recent decades, yet a scientometric analysis objectively mapping scientific knowledge and recent trends remains unpublished. Using relevant keywords, we conducted a search in the Web of Science Core Collection on September 23, 2022, retrieving a total of 47,681 documents with 987,979 references. We identified two prominent research trends: ‘noninvasive brain stimulation’ and ‘invasive brain stimulation.’ These methods have interconnected over time, forming a cluster focused on evidence synthesis. Noteworthy emerging research trends encompassed ‘transcutaneous auricular vagus nerve stimulation,’ ‘DBS/epilepsy in the pediatric population,’ ‘spinal cord stimulation,’ and ‘brain-machine interface.’ While progress has been made for various neurostimulation interventions, their approval as adjuvant treatments remains limited, and optimal stimulation parameters lack consensus. Enhancing communication between experts of both neurostimulation types and encouraging novel translational research could foster further development. These findings offer valuable insights for funding agencies and research groups, guiding future directions in the field.

1. Introduction

Two-thousand years ago, Scribonius Largus, the physician of the Roman emperor Claudius, suggested that applying electric currents on the cranial surface using a torpedo-fish could be a remedy for headaches (Jocks, 2013). More recently, in the 19th century, electricity from fish was also used to treat a variety of neurologic and psychiatric disorders (Kellaway, 1946). Later, in 1831, Michael Faraday introduced the concept of electromagnetic induction with the generation of a variable magnetic field by running electricity through a coil (Ziemann et al., 2008). In the late 1930s, the electroconvulsive therapy (ECT) device was invented by two neuropsychiatrists, Ugo Cerletti and Lucio Bini, as a substitute for the prior induction of seizures with Metrazol (Fink, 1984). These developments have led to modern clinical neuro modulation, an interdisciplinary field characterized by the use of electricity to modify abnormal brain activity and, consequently, ameliorate neuropsychiatric symptoms. Its techniques can be broadly divided into noninvasive brain stimulation (NIBS), repetitive transcranial magnetic stimulation (rTMS), transcranial electrical stimulation (tES), transcranial alternating current stimulation (tACS) (Antal et al., 2008), and transcranial direct current stimulation (tDCS) (Brunoni et al., 2012), as well as convulsive therapies (such as electroconvulsive therapy (ECT) and magnetic seizure therapy (MST)). These forms of NIBS are distinct from invasive neuro modulation IBS (such as vagus nerve stimulation (VNS) (Zabara, 1992) and deep brain stimulation (DBS) (Oliveria, 2018)). rTMS and tES are performed in ambulatory settings, do not require sedation and are very well tolerated. In turn, ECT and MST are techniques that use sedation and induce seizures, and most IBS techniques are neurosurgical procedures that implant pacemakers connected to brain structures. The approval by the US Food and Drug Administration (FDA) of DBS for the treatment of Parkinson’s disease in 2002 was a pivotal point in its large and rapid adoption, despite initial and controversial development in the late 1980s (Oliveria, 2018). With direct intervention in pathological neural circuits, DBS has changed the way that brain disorders are treated and understood and is considered one of the most promising therapeutic applications for clinical neuroscience (Lozano et al., 2019).

Patients with refractory neuropsychiatric disorders are treated by a interdisciplinary clinical team, including psychiatrist, neurologists, psychologists, neurosurgeons and others. Despite having similarities regarding animal models and technology development, it is unclear how well connected the field is, who the leading researchers and institutions are, and which topics are currently driving the field. In the past two decades, the number of scientific publications on brain stimulation has increased exponentially, which has made it possible to qualitatively and quantitatively summarize this body of research in systematic reviews and meta-analyses, respectively (Razza et al., 2021). However, these evidence synthesis methods are not well suited to identify and analyze trends within knowledge domains. A novel evidence synthesis method is referred to as the “research weaving framework”, as proposed by Nakagawa and colleagues, and combines bibliometrics and systematic mapping analyses (Nakagawa et al., 2019). Systematic mapping is a nascent method derived from systematic reviews, with the goal of classifying research on a broad topic. Bibliometrics is a quantitative evaluation of the structure of scientific knowledge based on citations, namely, a performance analysis. The combination of bibliometrics and systematic mapping is conducted with scientometrics analysis, with the aim of mapping scientific knowledge by analyzing performance, influence and research trends over time (Sabe et al., 2022).

Although a few bibliometric analyses have been recently published, they primarily focused on specific topics such as DBS and tDCS (Hu et al., 2017; Sun et al., 2022) or were limited to certain time periods (Zheng et al., 2020). However, a comprehensive overview of various neurostimulation techniques, examining the evolution of research across disciplines such as psychiatry, neurology and neurosurgery, is still lacking. Therefore, we decided to conduct a comprehensive scientometric analysis of research focusing on the clinical aspects of neurostimulation interventions encompassing NIBS and IBS. Our primary objective was to evaluate how knowledge domains of brain stimulation have evolved over the past decades by retrieving co-cited reference networks. Our secondary objective was to provide a measure of the research network (countries, institutions, authors and journals) and to detect potential research gaps and limitations.

2. Methods

This study was conducted according to a protocol based on a previously published large-scale scientometric analysis (Sabe et al., 2022) that can be found in the Open Science Framework (osf.io).

2.1. Search strategy and data collection

Data were collected from the Science Citation Index Extended in the Web of Science (WOS) Core Collection database. WOS is considered one of the most suitable databases for scientometric analysis (Mongeon and Paul-Hus, 2016), as it contains the full list of references and citations of each article from 1900 – citations that are not available in PubMed or Embase – and that were extracted in tag-delimited plain text files on September 23, 2022. The search terms used were a combination of keywords and MeSH terms related to brain stimulation. To focus on clinical aspects of brain stimulation, we excluded animal studies by excluding specific keywords. The full list of search terms is reported in our protocol (osf.io).

Included publications types were ‘article’, ‘reviews’, ‘editorial material’ and ‘proceedings papers’ with no restrictions on publication date or language. Duplicates were removed with CiteSpace.

To assess the quality of the retrieved articles, we conducted a
filtering process using statistical values with a confidence level of 95% and a confidence interval of 10%. For a dataset of 20,000 citations, we inspected 2,000 randomly selected articles with a maximum of 100 irrelevant references. Furthermore, we inspected all highly cited WOS articles, which are papers that perform in the top 1% of cited papers in the same field. Reasons for the exclusion of articles are reported in Supplementary Figure 1 and Supplementary Table 1.

2.2. Data analysis

Two different tools were used for analysis. The Bibliometrix R package (4.0.0)(Aria and Cucurullo, 2017) was used to obtain information on authors and journals. CiteSpace is a Java application used for scientometrics. We used CiteSpace (6.1. R2)(Chen, 2006) to retrieve co-cited networks using reference, authors, institutions and countries, and co-occurrence networks with keywords as units of measures.

The citation count is the number of direct citations of a publication. Co-citation analysis extracts pairs of papers that are cited together in a source article (Small, 1973), and co-occurrence networks are the counting of paired data within a collection unit. Different metrics are used in CiteSpace to generate network analyses, with structural (betweenness centrality, modularity, silhouette score) and temporal metrics (citation burstness) as a combination of both (sigma metrics). Betweenness centrality quantifies the number of times a node acts as a bridge along the shortest path between two other nodes (Freeman, 1977). Nodes with the highest centrality tend to be at the center of networks. The modularity score (Q) is a measure of the structure of a graph, measuring the density of connections within a module or community. The Q score ranges from 0 to +1. For Q values greater than 0.3, the cluster structure is considered significant, and higher values indicate a well-structured network. The silhouette score (S) is a metric used to calculate the goodness of a clustering technique (Rousseeuw, 1987). S scores range from −1 to +1. If the silhouette score exceeds 0.3, 0.5, or 0.7, the network is considered homogenous, reasonable, or highly credible, respectively. The generated clusters are labeled by CiteSpace based on noun phrases of the keyword lists of articles using the likelihood ratio test (p < 0.001).

Burstness is the intermittent increase and decrease in activity or frequency of an event over a specific time period. The retrieved dataset can thereby be reduced if CiteSpace detects specific time slicing by excluding empty intervals. Finally, Sigma is a metric of CiteSpace that combines burstness and betweenness centrality: (centrality +1)burstness (Chen, 2006). The sigma metric estimates the influence of a node, with higher scores indicating higher influence. We report CiteSpace parameters in Supplementary Information 1.

3. Results

3.1. Analysis of publication outputs and growth trend prediction

We retrieved 47,681 documents, encompassing 987,979 references from 3,383 sources (e.g., books, journals) published between 1910 and 2022.

The earliest paper identified was an experimental study published in 1911 that examined the effect of mechanical stimulation of the vagus nerve (Robinson and Draper, 1911).

The annual scientific production only started to grow in 1990 (n = 22 per year), with exponential growth (average growth rate per year of 18.34%) reaching a peak in 2021 (n = 4069) (Supplementary Figure 2). We identified 116,310 authors with an average of 5.72 co-authors per document. The average citation per document per year was 0.6 in 1990 and increased exponentially, reaching a peak in 2014 (4.7). The average citation per document was 35.28 (Supplementary Figure 3).

4. Analysis of clusters of research


We retrieved a co-cited reference network that gathered landmark references and clusters of research (Fig. 1). CiteSpace slicing reduced the 1901–2022 time frame to 1990–2022, excluding empty citation intervals. This co-cited reference network (1990–2022) gathered 22 clusters describing a two-tailed comet with two major trends of research on NIBS and IBS. The modularity score was significant (Q = 0.842), and the mean weighted silhouette score (S = 0.928) suggested highly credible clusters.

The first and oldest major trend on ‘noninvasive brain stimulation’ included four minor trends: ECT (clusters #12, #19, #23, #28), TMS (#1, #4, #5, #7, #14, #18, #24), transcranial direct current stimulation (tDCS) (#2, #0), and transcranial alternating current stimulation (tACS) (#13). The second major trend concerned ‘invasive brain stimulation’, with a trend regarding DBS for Parkinson disease (#3, #6, #9, #10, #16) and various psychiatric and neurological conditions (#11, #17, #20), in parallel to a weaker trend regarding VNS (#15, #8). In the last decade, both major trends of research fused into clusters that focused on evidence synthesis (#0, #4, #10, and #19). Finally, the network time map revealed that the most recently active clusters are clusters #0, #4, #6, #8, and #19 (Supplementary Figure 4).

We subsequently detail the cluster numbers, labels, cluster silhouette score (S), size (N), and mean year (Y) of co-cited articles and the articles with the highest betweenness centrality. The NIBS trend started with a relatively isolated, minor trend on ECT, with cluster #12 ‘ECT’ (1; 74; 1993)(Sackei, 1994), which evolved into cluster #28 ‘ECT/depression’ (0.997; 19; 1999)(Prudic et al., 1996), highlighting the efficacy of ECT for depression. This was followed by a focus on the combination of ECT with antidepressant effects of NMDA antagonists for treatment-resistant depression (TRD) #23 ‘ECT/ketamine’ (0.997; 19; 2015)(Li et al., 2010), and more recently, evidence synthesis on ECT #19 ‘ECT/depression/evidence synthesis’ (0.997; 42; 2019)(Joshi et al., 2016).

The second minor trend concerned rTMS, with a similar initial focus on depression as shown in cluster #18 ‘NMDAr/depression’ (0.998; 49; 1994)(Bliss and Collingridge, 1993), TMS mechanisms of action with #1 ‘TMS’ (0.969; 347; 1995)(Ziemann et al., 1996), and #7 ‘tRMTs/TRD’ (0.968; 187; 2000)(Pascual-Leone et al., 1996). Exploration of rTMS application continued with #5 ‘rTMS/theta burst stimulation (TBS)’ (0.889; 246; 2007)(Huang et al., 2005), #14 ‘rTMS/neuropathic pain’ (0.983; 64; 2011)(Lefaucheur et al., 2014), and more recent applications, e.g., in neurosurgery #24 ‘preoperative nTMS/cortical mapping’ (0.998; 18; 2015)(Picht et al., 2013).

The ‘noninvasive brain stimulation’ trend continued with two minor trends. First, tDCS with #2 ‘tDCS’ (0.99; 326; 2010)(Nitsche et al., 2008), with the largest cluster of the network, cluster #0 ‘tDCS/DBS evidence synthesis’ (0.882; 428; 2017)(Nitsche and Paulus, 2000), and tACS, #13 ‘tACS’ (0.982; 68; 2015)(Helfrich et al., 2014).

The second major trend, ‘invasive brain stimulation’, mainly concerned the use of DBS for Parkinson’s disease, with DBS of the subthalamic nucleus, cluster #3 ‘DBS/Parkinson’s disease’ (0.956; 269; 2002)(Krack et al., 2003), which continued with cluster #16 (0.972; 57; 2009)(Gradinaru et al., 2009) on the neuropathophysiology of Parkinson’s disease, and several randomized controlled trials (RCTs) with #9 (0.981; 24; 2011)(Schuepbach et al., 2012). More recently, research on the use of DBS for Parkinson’s disease has been very dynamic, with innovative options #6 ‘DBS/Parkinson disease/Magnetic Resonance-guided focused Ultrasound Surgery (MRFUs)/thalatomy (0.915; 226; 2018)(Horn et al., 2017). DBS has also been used for treatment-resistant depression (TRD), cluster #11 ‘DBS/TRD’ (0.959; 125; 2000)(Mayberg et al., 2005), and for different psychiatric and neurological conditions, such as #20 ‘DBS/cluster headache’ (0.993; 40; 2004)(Schoenen et al., 2005) and #17 ‘DBS/dystonia’ (0.974; 52; 2006).
A second and minor trend was observed regarding VNS with cluster #15 (0.996; 62; 2000) (Handforth et al., 1998) and, recently, drug-resistant partial epilepsy #8 ‘VNS/epilepsy’ (0.965; 165; 2018) (Salanova et al., 2015).


To further explore the latest research trends, we retrieved the reference networks from the last two years with monthly slices (2020–2022) (Supplementary Figure 5). The modularity score was significant, and the mean weighted silhouette suggested highly credible clusters (Q = 0.635; S = 0.871). Previous clusters on evidence synthesis were detected (clusters #0, #1, #2, #4, #5, and #6); however, more specific applications of VNS have been found, such as cluster #3 ‘transcutaneous auricular VNS (taVNS)’ (0.956; 269; 2020) (Frangos et al., 2015), and novel small clusters delineating new frontiers to brain stimulation research were also identified, such as cluster #13 ‘DBS/epilepsy pediatric population’ (0.992; 8; 2021) (Nair et al., 2020), cluster #9 ‘spinal cord stimulation’ (0.985; 25; 2020) (Kapural et al., 2016), and cluster #10 ‘brain-machine interface’ (0.998; 25; 2020) (Musk, 2019).

4.3. Most highly cited papers

The most cited articles according to our datasets are reported in Table 1. The three most cited papers were the Nitsche and Paulus (2000) clinical trial on excitability changes with tDCS (Nitsche and Paulus, 2000) and two clinical guidelines on the use of NIBS techniques, namely, Rossi et al. (2009) and Rossini et al. (2015) guidelines for rTMS (Rossi et al., 2009; Rossini et al., 2015). The burstness analysis proposed that for the 2020–2022 time period, the three papers with the latest and most important strength of burst were Lefaucheur, et al. (2014) evidence-based guidelines, Ashkan and colleagues’ 2017 review on the mechanisms of DBS (Ashkan et al., 2017), and Lozano and colleagues’ review on the future direction of DBS (Lozano et al., 2019) (Table 1).

We conducted a structural variation analysis for the 2020–2022 time period focused on novel boundary-spanning connections to detect the best candidates for transformative papers (Supplementary Table 3). The three papers with the most transformative potential for the 2020–2022 network were the Rossi et al. (2021) safety and recommendations guidelines for TMS (Rossi et al., 2021), the Fregni and colleagues 2021 evidence-based guidelines on tDCS for neurological and psychiatric disorders (Fregni et al., 2021), and the Krauss and colleague review on future directions of DBS (Krauss et al., 2021).

4.4. Co-occurring authors’ keyword networks

Co-occurring keywords can inform the latest trends and possibly future directions of research. We retrieved the co-occurring author’s keyword networks of the last five years (2016–2022) (Fig. 2). The network presented a significant modularity score (Q = 0.4738) and a highly credible weighted mean silhouette score (S = 0.7193). Nine different clusters were identified: #0 ‘TMS’ (0.695; 203; 2016), #1 ‘functional connectivity’ (0.628; 197; 2017), #2 ‘DBS’ (0.695; 203; 2016), #3 ‘microglia’ (0.695; 203; 2016), #4 ‘ECT’ (0.695; 203; 2016), #5 ‘VNS’ (0.695; 203; 2016), #6 ‘spinal cord stimulation’ (0.695; 203; 2016), #7 ‘diffusion tensor imaging’ (0.695; 203; 2016), and #8 ‘cochlear implant’ (0.695; 203; 2016). Clusters #3, #4 and #7 were less active in 2022 than other clusters. The burstness analysis proposed among the keywords with the most recent and strongest bursts of co-occurrence was ‘machine learning’, ‘deep learning’, ‘neural network’, ‘rTMS’ and ‘ECT’ (Supplementary Table 2).

4.5. Analysis of cooperation across countries and institutions and growth trend prediction

A total of 135 countries were identified. The three countries...
Table 1
The top 10 most co-cited references.

<table>
<thead>
<tr>
<th>Number of citations in the network/ Number of citations in the literature</th>
<th>Source</th>
<th>Vol</th>
<th>Page</th>
<th>Title</th>
<th>Doi</th>
<th>Type of study</th>
<th>Related cluster in Fig. 1</th>
</tr>
</thead>
</table>

* Number of citations in the literature in December 2022 according to the journal where the paper was published

associated with the highest number of citations were the USA (n = 15,216), Germany (n = 5895) and the UK (N = 4415). The co-cited author’s country network can inform the international collaborative network. We retrieved the 1990–2022 co-cited author’s country network (Fig. 3. A). The USA is the country with the most significant betweenness centrality (0.99); however, the sum of the European countries followed up to fifth place with the United Kingdom (0.23), Italy (0.22), Spain (0.20), Germany (0.18) and France (0.16). China was only in fifth place of citation counts (n = 3692); nevertheless, these citations mostly occurred since 2019 with an outstanding citation burst strength (356.86) (Supplementary Table 4). The burstness analysis revealed the start of this in the USA beginning in 1990, i.e., This is the country with the oldest citation burst..

For institutions, 645 different institutions were identified. The three most cited institutions were Harvard University (n = 1882), University of California (n = 1667), and University of Toronto (n = 1472). We focused on the last five-year collaborative networks to retrieve the most recent dynamics. We therefore retrieved the 2016–2022 co-authors’ institutions network (Fig. 3. B) that presented a significant modularity score (Q=0.4) and a highly credible mean weighted silhouette score (n = 0.786). Eight different clusters were identified. The largest cluster was USA network #0. Although being the fifth largest cluster, Chinese network #5 was placed relatively outside of the European and American collaborative networks. The top three institutions with the greatest centrality scores were Harvard University (167.09; 1998), the National Institute of Neurological Disorders and Stroke (52.19; 1991), and the National Institute of Mental Health (4.13; 1994) (Supplementary Table 4). The burstness analysis revealed that the three institutions with the latest strength of burst were Nagoya University (8.47; 2020), Nantong University (8.15; 2020) and Sorbonne University (8.15; 2020) (Supplementary Table 2).

4.6. Analysis of co-authorship networks

A total of 116,310 authors with a mean of 5.72 co-authors per article were found in our dataset. The co-authorship network connects authors that share the authorship of a paper, informing the individual’s body of research and the global collaborative network. We extracted the co-author collaborative network of the last five years (2016–2022) (Supplementary Figure 5). The modularity score was significant (Q=0.747), and the weighted mean silhouette score indicated highly credible clusters (S=0.928). Nineteen different clusters were regrouped in a single network, gathering co-authors around the same topic of research, such as cluster # ‘functional connectivity’, which gathers mostly Chinese authors, and #2 ‘Parkinson disease’ with European and American researchers.

The burstness analysis indicated that the three co-authors with the most recent and important strength of burst were Zhang Chencheng...
6. Analysis of co-cited journals

We found 2792 journals in our dataset. The three journals with the most important and most recent growth of publications were Clinical Neurophysiology (n = 927), Brain Stimulation (n = 875), and Journal of ECT (n = 829) (Supplementary Figure 7). Furthermore, the journals with the most citations were Neurology (n = 18,740), Journal of Neuroscience (n = 18,108), and Brain (n = 18,071). The author’s journal co-citation network can inform on the most suitable journals for publication. This network (1990–2022) presented significant modularity (Q=0.6649) and a highly credible silhouette score (S=0.8341) and gathered 11 clusters (Supplementary Figure 8). The most central and largest cluster was cluster #0 ‘brain stimulation journals’, which gathered impactful neurology journals. Smaller clusters were also emerging on novel topics, cluster #10 ‘biomedical engineering journals’ and #11

Fig. 2. Co-citation references network (1990–2022) with highlight of clusters obtained with CiteSpace. The two major research trends are delimited with distinct colors, orange for ‘non-invasive brain stimulation’ trend, green for the ‘invasive brain stimulation’ trend. The position of the node (article) corresponds to the year of publication. The size of a node is proportional to the number of times the node has been co-cited. For each cluster, a single color is attributed.

Fig. 3. Timeline visualization of co-occurring author’s keywords networks (2016–2021). Each node refers to a highly co-occurring keywords. Nodes diameters and links thickness are proportional to the burstness of keywords co-occurrence. Each retrieved cluster gathers node on different horizontal time lines according to the mean year of co-occurrence.
The burstness analysis revealed that the three journals presenting the most recent strength bursts were Scientific Reports (908; 2019), Frontiers in Neuroscience (568.23; 2019), and Frontiers in Neurology (421.7; 2019).

5. Discussion

This comprehensive scientometric analysis included 47,681 documents, encompassing almost a million references that were published over the past century and mainly in the last 30 years. This broad synthesis allowed us to retrace the history of research on neuromodulation techniques and uncover the most influential research trends.
Furthermore, the most prominent papers, journals, and authors were identified, which can also be used in grant proposals and inform policymakers and funding agencies.

5.1. Research trend dynamics, future of research

The co-cited reference network exposes a gradual deployment of clusters that follows the different degrees of maturity and body of evidence. ECT has been studied since the 1940s and formed the first identified cluster (#12). TMS was developed in the 1980s (#1), whereas modern methods of tES (tACS and tDCS) were developed after 2000 (#2, #13). However, new variants of these techniques, such as theta-burst stimulation and tACS, were only clinically investigated in the 2010s (#0). The same pattern is found for invasive neuromodulation with VNS (#15) to DBS (#16). Of note, both ECT and VNS present a renewed interest with newly formed clusters (#8 ‘VNS/epilepsy’, #23 ‘ECT/ketamine’). Furthermore, as found in many scientometric studies conducted in psychiatry (Cortese et al., 2022; Sabe et al., 2022), networks are marked by similar patterns reflecting the development of distinct research fields: neuroimaging between 1990, evidence synthesis by 2000, and more recently with innovative research methods (e.g., machine learning, deep learning). Of note, the two major research trends on invasive and NIBS start to converge by 2010, which might lead to more translational research.

The latest research trends focus on very specific and innovative applications of neurostimulation, with tVNS, that could potentially be combined with ear-EEG to modulate attention as a closed-loop portable NIBS (Ruhnau and Zaehle, 2021). Moreover, DBS application for epilepsy in pediatric populations might represent a breakthrough in improving access to treatment options for this specific population. In addition, the detection of a cluster on spinal cord stimulation indicates the maturation of evidence with the recent conduction of several RCTs on chronic pain (Deer et al., 2018).

One final cluster holds many promise for the use of brain-machine interfaces to restore sensory and motor function, with a focus on scalability and miniaturization (Musk, 2019)(e.g., nanoelectronic probes for glial scar-free neural integration).

5.2. Clinical relevance of neuromodulation interventions and public mental health policies

The significant growth of evidence synthesis contributed to the generation of hallmark papers that impulse research and lay down public mental health policies. Although the initial history of ECT is very controversial, it was the first neurostimulation intervention to receive US Food and Drug Administration (FDA) approval in 1976 on the basis of long-standing prior experience. ECT presents significant effects on resistant and disabling forms of depression and schizophrenia supported by extensive scientific data (Prudic et al., 1996) but has also greatly benefited thousands of patients with severe forms of other conditions. Consistent with these findings, ECT currently holds the highest popularity and expectation index among neuromodulation interventions (Tran et al., 2019). Similarly, DBS sparked controversy during its development in the late 1980s by Alim Benabid (Oliveria, 2018) and was the second intervention to receive approval from the FDA in 1996. DBS approved for essential tremor and severe tremor in Parkinson’s disease (FDA, 1997) followed approval for advanced forms of Parkinson’s disease in 2002 (FDA, 2002a) and for refractory focal epilepsy in 2017 (FDA, 2018c). The 2002 DBS approval for the treatment of Parkinson’s disease was a pivotal point in its large and rapid adoption. Nevertheless, DBS is only available to a small number of patients with refractory/resistant diseases. Thousands of patients benefited from rTMS approval in 2008 as a treatment to alleviate symptoms of mildly treatment-resistant depression, and in 2018 (McClimontock et al., 2018), rTMS was further approved for obsessive-compulsive disorder (FDA, 2020). More recently, RCTs have been conducted to evaluate and define home-based tDCS for major depressive disorder (Cappon et al., 2021), as tDCS still needs to be regulated and approved in clinical practice based on adequate RCTs. Other promising neuromodulation interventions have recently been approved as the Stanford Accelerated Intelligent Neuromodulation Therapy (Cole et al., 2020).

5.3. Maturity and body of evidence

Although the two major research trends on invasive and NIBS start to converge by 2010 with a particular focus on evidence synthesis, the most co-cited articles mainly focus on guideline papers for the major trend on NIBS and more on RCTs for DBS, reflecting distinct maturity and a body of evidence (Table 1). Indeed, while the development of evidence has greatly improved in recent decades, with numerous RCTs being conducted and several of these techniques being approved and/or showing level A evidence (Table 2), the level of evidence differs for each neuromodulation intervention and for each mental disorder. For instance, there is a stronger evidence base for treating resistant depression with tRMS than for treating resistant hallucinations in schizophrenia. Furthermore, although we have several RCTs for specific populations, the selection criteria used by the authors vary across studies. Of note, most individual studies included small sample sizes and are underpowered. Moreover, for most neuromodulation interventions, there is no solid consensus regarding optimal stimulation parameters, cumulative doses, and even neural targets for some disorders.

<table>
<thead>
<tr>
<th>Year</th>
<th>Neurostimulation interventions</th>
<th>FDA approval or current evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>DBS</td>
<td>VIM-DBS for essential tremor and severe tremor in PD (FDA, 1998)</td>
</tr>
<tr>
<td>1997</td>
<td>VNS</td>
<td>Adjunctive therapy in reducing the frequency of seizure in pharmaco-resistant epilepsy (FDA, 2017)</td>
</tr>
<tr>
<td>2002</td>
<td>DBS</td>
<td>DBS for dystonia and treatment of advanced PD (FDA, 2002b)</td>
</tr>
<tr>
<td>2005</td>
<td>VNS</td>
<td>VNS for resistant depression (FDA, 2015)</td>
</tr>
<tr>
<td>2024</td>
<td>DBS</td>
<td>Possible future evaluation of DBS for refractory depression (FDA, 2024)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Neurostimulation interventions</th>
<th>FDA approval or current evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>ECT</td>
<td>Regulated through “the premarket notification” as an intermediate and low risk device (JSC, 1976)</td>
</tr>
<tr>
<td>2008</td>
<td>rTMS</td>
<td>Treatment of MDD in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode (Demitrack et al., 2010)</td>
</tr>
<tr>
<td>2013</td>
<td>rTMS</td>
<td>Treatment of chronic pain and migraine (FDA, 2013)</td>
</tr>
<tr>
<td>2015</td>
<td>Deep TMS</td>
<td>For treatment-resistant depression and MDD (Leckovic et al., 2015)</td>
</tr>
<tr>
<td>2018</td>
<td>ECT</td>
<td>Reclassification of ECT devices, for use in treating catatonia or a severe major depressive episode (MDE) associated with major depressive disorder (MDD) or bipolar disorder (BDP) in patients age 13 years and older who are treatment-resistant or who require a rapid response due to the severity of their psychiatric or medical condition (FDA, 2018a)</td>
</tr>
<tr>
<td>2018</td>
<td>Deep TMS</td>
<td>Treatment of OCD (FDA, 2018c)</td>
</tr>
<tr>
<td>2018</td>
<td>TBS</td>
<td>TBS for the treatment of MDD (FDA, 2018d)</td>
</tr>
<tr>
<td>2020</td>
<td>Deep TMS</td>
<td>Treatment of smoking addiction (Zangen et al., 2021)</td>
</tr>
<tr>
<td>2022</td>
<td>iTBS</td>
<td>Stanford Accelerated Intelligent Neuromodulation Therapy (SAINSTM neuromodulation system) for MDD (Cole et al., 2020)</td>
</tr>
<tr>
<td>2024</td>
<td>tDCS</td>
<td>Future evaluation of define home-based tDCS for major depressive disorder (FDA, 2024)</td>
</tr>
</tbody>
</table>
limitations raise important conceptual questions. For example, should clinical relevance estimation be based on changes in clinical scales, and how large should a change be to be considered clinically meaningful? Moreover, the mechanism of action of neuromodulation interventions is to modify neuronal plasticity, connectivity and networks; therefore, specific symptoms (e.g., hallucinations, impulsivity, apathy) could be more appropriate therapeutic targets than diagnostic categories (Tracy and David, 2015). To address these concerns, various techniques are used to evaluate the impact of neuromodulations interventions, such as the functional near-infrared spectroscopy (Husain et al., 2020) or machine-learning (Li et al., 2022). Furthermore, ongoing research is focused on identifying the neuroanatomical substrates to optimize clinical responses (Elia et al., 2020).

These questions are pertinent, considering that although these interventions have proven to be effective in the short term across multiple mental disorders and on multiple outcomes (Hyde et al., 2022; Rosson et al., 2022), the effect sizes obtained, the duration of effects, the replication, and the reliability of various techniques are still limited (Terranova et al., 2019). As such, the application of rTMS requires considerable expertise; however, most considered studies have not used MRI-based neuronavigation. More high-quality RCTs with clear inclusion criteria, including arms with different stimulation parameters, could improve the level of evidence. For neuromodulation interventions other than rTMS, the level of evidence is even thinner or stimulates intense debate, such as with ECTs, which need more high-quality RCTs, although the comparison of ECTs to placebo is not appropriate (CADTH, 2015; Meechan et al., 2022). Although the current evidence base is weak, important hopes lie in iDCS research, which is less expensive than rTMS and easy to apply (Fregni et al., 2021). Finally, evidence is still sparse regarding VNS and trigeminal nerve stimulation for depression, with mostly open unmasked trials being conducted thus far.

Another important aspect of clinical practice is the cost-effectiveness of these interventions for patients with treatment-refractory conditions (McLoughlin et al., 2007; Zemplenyi et al., 2022; Zhao et al., 2018). For instance, DBS is seen as a cost-effective treatment strategy for advanced PD (Pietzsch et al., 2016) but not necessarily for depression (Widge et al., 2018). Nevertheless, these interventions remain highly expensive and are still mostly only accessible in Western countries and are very poorly covered by health insurance. The financial burden and fear of adverse effects are the main key reasons to limit the use of neurostimulation interventions.

6. Limitations

Different limitations impact this scientometric analysis. The most important limitation is linked to the nature of gathered data, from only one database, WOSCC. Indeed, for most databases, full text and citation analyses are not available. Furthermore, the combination of different databases is currently not possible considering digital object identifier errors between databases, which affect the accuracy of determined coverage differences (Francuite, 2021).

Moreover, the use of citation-related indicators in scientometric analysis can be a potential source of different biases, such as citation bias, where the probability of being cited depends on the outcome of a study (Jannot et al., 2013). Another frequent bias is citation distortions, where unfounded authority can emerge due to distorted social citations with important co-citation, establishing unfounded scientific claims as fact (Greenberg, 2009). Although a retrieved network can deliver an accurate picture of a research network, different limitations must be acknowledged, such as the limitation of most co-cited articles in the co-citation network. Another limitation related to our own field of research is that papers on DBS trends might be less likely to be co-cited, with a more limited amount of publication compared to the NIBS trend, in particular, due to ethical issues in DBS treatment and research (Muñoz et al., 2020).

Finally, considering the delay of recognition of a publication, due to the fact that citations of a publication typically peak from one to three years after the publication, the most recent impacting papers or trends could have been missed.

7. Conclusion

The field of neuromodulation interventions is rapidly expanding and remains controversial, somewhere between hopes for innovative therapies to alleviate treatment-refractory symptoms and the reality of adverse effects and financial burden of some interventions. This scientometric analysis produced a snapshot of the history of research on neuromodulation interventions, the current knowledge domains and the latest emerging trends. In the last decade, the two major research trends identified on NIBS and IBS share citations, and the potential future research trends concern specific and innovative applications of neurostimulation, such as taVNS, DBS application in a pediatric population, spinal cord stimulation, and brain-machine interface. Despite these preliminary findings of some interventions being promising, the current evidence base is still heterogeneous. In clinical practice, the approval process by the FDA remains dawdled on evidence-based proofs, and ethical and legal concerns persist with regard to potential misuse or overuse. This work may be useful for determining future research topics that can be integrated into grant proposals.

Funding

Internal funding only.

CRediT authorship contribution statement


Declaration of Competing Interest

Marco Solmi has received honoraria/has been a consultant for Abbvie, Angelini, Lundbeck and Otsuka. Michael A. Nitsche is a member of the scientific advisory board of Neuroelectrics. Andre R Brunoni holds a small equity of FlowNeuroscience and has been scientific advisor of the company between 2016 and 2018. He also receives research grants from the São Paulo Research State Foundation (19/06009–6) and the Academy of Medical Sciences (NAFR 12/1010) and in-kind support from MagVenture and SoterixMedical. Othman Sentissi has received advisory board honoraria from Otsuka, Lilly, Lundbeck, Sandoz, and Janssen in an institutional account for research and teaching. André Aleman, Luc Mallet, Jonathan Downar, Marom Bikson, Valerie Brandt, Chaomei Chen, Adi Sulstarova, Emmanuel Poulet, Joshua Hyde, Samuele Cortese and Michel Sabe report no conflicts of interest.

Data Availability

The data used in the analyses of this manuscript are available upon request.

Acknowledgments

None.
Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.neubiorev.2023.105300.

References


M. Sabi et al.
Neuroscience and Biobehavioral Reviews 152 (2023) 105300


